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FIGURE 1
Matched IL-6 Quantification

INTRODUCTION
•

•

•
•

•
•

Endocrine therapies and cdk4/6 inhibitors have
improved clinical outcomes and progressionfree survival in metastatic hormone receptor
positive (HR+), human epidermal growth factor
2 negative (HER2-) breast cancers (1).
Early-stage breast cancer patients benefit
initially from endocrine therapies, but most
breast cancers eventually develop de novo or
acquired resistance to cdk4/6i (2, 3).
Mechanisms of cdk4/6i resistance in HR+
breast cancers are due mainly to endocrine
therapy insensitivity (4).
Multiple pathways involved in the development
of resistance have been identified. However,
Improved clinical outcomes remain largely
limited after development of resistance and
disease progression.
Focusing on clinical biomarkers contributing to
resistance helps identify disease progression.
Interleukin-6 promotes tumor survival and
progression and could be investigated as a
potential biomarker.
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MATERIALS & METHODS
•
•
•

Reagents: R&D Systems Quantikine Human
IL-6 ELISA kit
Patient Samples: Blood drawn from HR+,
HER2- breast cancers at certain treatment
timepoints and obtained through the clinic
ELISA: Extracted plasma from patient blood
samples to detect IL-6 levels throughout
treatment timepoints
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Figure 3. IL-6 levels obtained through ELISA on plasma samples from
metastatic HR+, HER2- breast cancer patients currently on cdk4/6i
treatment were plotted. Patients were identified by PA and study number
in order instead of medical record numbers for HIPAA compliance.

RESULTS & DISCUSSION
Figure 1. (A) Biospecimen collection was prospectively planned and collected
from patients consented to the study at baseline, on treatment cdk4/6i timepoints
at months 1, 4, 8, 12, and progression. Biospecimens collected included blood,
serum, plasma, peripheral blood mononuclear cells (PBMCs), and circulating
tumors cells (CTCs). (B) IL-6 was quantified through ELISA on patient plasma,
where plasma was obtained by centrifugation of blood samples and collection of
the resulting top-most layer. IL-6 levels were matched to their respective patients
that had available blood samples at pre and post cdk4/6i timepoints.

FIGURE 2
Unmatched IL-6 Quantification

Additional Details:
• Blood samples were drawn from patients at
baseline, timepoints at months 1, 4, 8, 12 into
cdk4/6i treatment, and at progression
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On Treatment IL-6 Levels
A

HYPOTHESIS

IL-6, a potential biomarker for endocrine therapy
resistance, can be used to predict response to
endocrine therapies in HR+, HER2- breast
cancers. As an upregulator for tumor survival, IL-6
levels will increase during disease progression.
Investigation into biomarkers will help determine
additional therapies and give a better indication of
metastatic HR+, HER2- breast cancer treatment
response to cdk4/6i.

FIGURE 3

Ø Of the patients in the study who progressed, IL-6 levels at
progression for those patients were higher than the IL-6
levels at baseline, even when IL-6 on-treatment trends
were variable across patients
Ø Upon compiling all IL-6 measurements from metastatic or
non-metastatic patients at baseline or progression, IL-6
levels in HR+, HER2- metastatic breast cancer patients
who have progressed (post cdk4/6i) are significantly higher
than IL-6 levels in metastatic patients at baseline (pre
cdk4/6i) or early-stage non-metastatic patients.
Ø In addition, metastatic patients at baseline have
significantly higher IL-6 plasma levels than the IL-6 levels
of non-metastatic early-stage breast cancer patients.
Ø IL-6 levels did not exhibit significant change in ontreatment stages where the tumor was stable and had not
yet developed therapeutic resistance.
Ø The sharp, significant increase in IL-6 levels during
progression compared to baseline strongly suggests IL-6 is
an important biomarker for resistance to endocrine
therapies in HR+, HER2- breast cancers.
Ø Further focus on IL-6 and other potential biomarkers
contributing to resistance would help better identify and
predict disease progression, allowing determination of
additional therapies and improved clinical outcomes.
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